Clinical trial
Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
NCT00073125 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00073125 |
|---|---|
| Title | Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma |
| Official title | A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | ABT-510/Thrombospondin-1 mimetic |
| Enrollment | 103 |
| Start date | May 1, 2003 |
| First posted | Nov 18, 2003 |
| Last update posted | Aug 15, 2007 |
| Countries | Netherlands, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: